Draft whole-genome sequence of Brevibacterium casei strain isolated from a bloodstream infection

Braz J Microbiol. 2020 Jun;51(2):685-689. doi: 10.1007/s42770-020-00236-x. Epub 2020 Feb 17.

Abstract

Despite its low virulence potential and a commensal lifestyle as a member of the human skin microbiota, Brevibacterium casei has been increasingly reported as an opportunistic pathogen, especially in immunocompromised patients. Here, we present the draft genome sequence of the S51 strain isolated from a bloodstream infection. To the best of the authors' knowledge, this is the first report of the draft genome sequence of the B. casei strain isolated from the clinical infection. The strain was identified using phenotypic and molecular methods and subsequently sequenced using the next-generation sequencing. The draft whole genome was assembled de novo, automatically annotated by Rapid Annotations using Subsystems Technology (RAST) server and scrutinized to predict the presence of virulence, resistance, and stress response proteins. The genome size of the S51 strain was 3,743,532 bp and an average G+C content was 68.3%. The predicted genes included 48 genes involved in resistance to antibiotics (including vancomycin, fluoroquinolones, and beta-lactams) and toxic compounds (heavy metals), 16 genes involved in invasion and intracellular resistance (Mycobacterium virulence operons), and 94 genes involved in stress response (osmotic, oxidative stress, cold and heat shock). ResFinder has indicated the presence of a beta-lactamase, and a phenotypic analysis showed resistance to penicillin. This whole-genome NGS project for the S51strain has been deposited at EMBL/GenBank under the accession no. QNGF00000000.

Keywords: Brevibacterium casei; Genome; Infection; Sequencing.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacteremia / microbiology*
  • Base Composition
  • Brevibacterium / drug effects
  • Brevibacterium / genetics*
  • Brevibacterium / isolation & purification
  • Drug Resistance, Multiple, Bacterial
  • Genome, Bacterial*
  • Gram-Positive Bacterial Infections / microbiology*
  • Humans
  • Sequence Analysis, DNA
  • Virulence
  • Whole Genome Sequencing

Substances

  • Anti-Bacterial Agents

Supplementary concepts

  • Brevibacterium casei